Compare AbCellera Biologics Inc (ABCL) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Avantis International Small Cap Value ETF — how do they compare? AbCellera Biologics Inc trades at $9.91 (market cap $2.99B), while Avantis International Small Cap Value ETF trades at $110.26. Which is the better fit depends on your goals.
| ABCL | AVDV | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $110.40 |
52-Week Low | $2.78 | $83.89 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
AVDV trades at $110.51, up 0.96% today, with a bullish technical outlook from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies gaining attention. The stock shows support near $108-$109 and resistance at $110.
The outlook remains positive due to momentum in international small-cap value, though overbought signals and reliance on commodity sectors pose risks. Investors should weigh the ETF's diversification benefits against potential volatility from global economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
